Safety and Efficacy Of ARRY-502, a Potent, Selective, Oral CRTh2 Antagonist, In Patients With Mild To Moderate Th2-Driven Asthma

Authors

Keywords

Journal

Volume 133, Issue 2, Pages AB4

Publisher

Elsevier BV

Online

2014-01-24

DOI

10.1016/j.jaci.2013.12.037

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now